It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in adverse events requiring cessation of study drug(s) compared with placebo/no antifungal/any other antifungal (low certainty).
Amitriptyline probably leads to higher overall tolerability Drop‐out due to adverse events compared with placebo (moderate certainty).
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
SSRIs or SNRIs showed no clear difference in withdrawn (for any reasons and due to adverse events) compared with amitriptyline (low certainty).
It is very uncertain whether aspirin changes adverse events in the child ‐ Congenital malformations compared with placebo (very low certainty).
Vitamin D supplementation may leads to lower maternal adverse events: severe postpartum haemorrhage compared with placebo or no intervention (low certainty).
The review found no eligible studies for this question.
Maribavir showed no clear difference in adverse events compared with ganciclovir (moderate certainty).
Mindfulness‐based interventions (MBIs) showed no clear difference in adverse events compared with non‐active comparators (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.